



# Barriers to Hepatitis C Treatment Persist from the Interferon-Era

Danielle K. Bäck<sup>1</sup>, Jasneet Aneja<sup>1</sup>, E. Nalan Ward<sup>2</sup>, and Arthur Y. Kim<sup>1</sup>

<sup>1</sup>Department of Medicine and <sup>2</sup>Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School



## Background

- Approximately 53% of people who inject drugs will acquire hepatitis C virus within 5 years<sup>1</sup>. Globally, an estimated 10 million people who use drugs have been exposed to HCV<sup>2</sup>.
- During the interferon-era, there were significant barriers to HCV treatment, especially for patients who use drugs.
- With the introduction of direct acting antivirals (DAAs), HCV cure rates have improved, but there may be continued barriers to treatment for patients with substance use disorder (SUD).

## Objectives

- To evaluate disparities in antiviral treatment for patients with HCV at the West End Clinic, a clinic for patients with concurrent substance use and psychiatric disorders.
- To follow Hepatitis C outcomes in a single cohort through both the pre-DAA and post-DAA eras, in a jurisdiction (Boston, Massachusetts, USA) where most insurers do not impose restrictions based on fibrosis or substance use.


## Methods

- The West End Clinic provides SUD care for patients with primary care at MGH, allowing integrated review of HCV treatment access.
- Out of 611 consecutive patients who underwent intake at the West End Clinic from 2008-2010, 141 were diagnosed with HCV and followed before and after the onset of the DAA era (in January 2014).
- Descriptive statistics were calculated and logistic regression analysis was performed to determine predictors of HCV treatment.

## Results

Demographics (n=141)		Substances Used	
Age (mean)	50.6 yrs	Alcohol	95.7%
Male	71.6%	Cocaine	84.4%
White race	92.1%	Marijuana	83.0%
Heterosexual	93.2%	Heroin	79.4%
IVDU	84.6%		
History of homelessness	31.4%		

HCV Cascade for Patients Followed through IFN and DAA Eras



\*5 patients failed interferon therapy and were re-treated with DAAs.

- SVR was attained in 42.3% of patients with IFN-based treatment and in 82.9% of patients treated with DAAs.
- Only 47.3% of HCV-positive patients actively followed during the DAA era received treatment.

Logistic regression was performed to compare those who received HCV treatment to those who did not:

- Predictors of HCV treatment included older age (OR=1.05, p=0.05).
- Predictors of a lack of HCV treatment included a history of IVDU (OR=0.08, p=0.02) and a history of homelessness (OR=0.30, p=0.05).

## Conclusion

- Despite access to specialists and few payor restrictions on antiviral treatment, only a minority of candidates for HCV treatment in a substance use clinic in Boston, MA, have received antivirals.
- Patients who were younger, currently or previously homeless, or had prior IVDU were less likely to receive HCV treatment.
- Although rates of SVR were higher with DAAs, barriers to HCV treatment during the interferon era persist into the DAA era.
- Barriers to hepatitis C antiviral treatment are multi-factorial and likely include lack of linkage to treatment, unstable housing, stigmatization of drug use, and provider bias<sup>3,4</sup>.
- Future efforts at HCV elimination in Boston, MA, should focus on overcoming barriers for these specific patient populations.

## References

1. Hagan, H, Pouget, ER, Des Jarlais, DC, and Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place, American Journal of Epidemiology 2008.
2. Nelson, PK, Mathers, BM, Cowie, B, Hagan, H, De Jarlais, D, Horyniak, D, and Degenhardt, L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews, Lancet 2011.
3. Asher, AK, Portillo, CJ, Cooper, BA, Dawson-Rose, C, Vlahov, D, and Page, KA. Clinicians' Views of Hepatitis C Virus Treatment Candidacy with Direct-Acting Regimens for People who Inject Drugs, Substance Use & Misuse 2016.
4. Wolfe, D, Luhmann, N, Harris, M, Momenghalibaf, A, Albers, E, Byrne, J, and Swan, T. Human rights and access to hepatitis C treatment for people who inject drugs, International Journal of Drug Policy 2015.